InAADR: Drug-Protein-ADRs database

InAADR

Enter Protein Name or Uniprot ID:

Protein Information

Protein Name:	Multidrug resistance protein 1 (P08183)
Gene Name:	ABCB1
Description:
PDB ID:
Protein Family:	PF00664, PS50929
Protein Category:	Transporters

Drug-Protein Interaction
Adverse Drug Reactions

This panel provides drug-protein interaction and their ADRs along with references

Interacting Drugs	Toxicity	Mechanism	Reference
Carvedilol	Left Ventricular Systolic Dysfunction	Inhibition of P-gp-mediated transcellular transport of diGOxin decreased circulation volume or plasma albumin level of hemodialysis patients@ which may lead to asymptomatic left ventricular systolic dysfunction [ ADR Type 4 ]	Efficacy of additional low-dose carvedilol in maintenance hemodialysis patients with asymptomatic left ventricular systolic dysfunction
Digoxin	Myelosuppression	Myelosuppression [ ADR Type 1 ]	Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele
Doxorubicin	Cytotoxicity	Inhibition of P-glycoprotein (PGP) activity by verapamil or PSC 833 enhances the Cytotoxicity of vincristine@ doxorubicin@ teniposide and taxol [ ADR Type 4 ]	P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells
Fluconazole	Hypersensitivity	Mild hypersensitivity [ ADR Type 5 ]	Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected
Ivermectin	Cytotoxicity	Ivermectin induces a clear inhibition on P-glycoprotein (PGP) basal ATPase activity@ thus increases the Cytotoxicity of verapamil [ ADR Type 4 ]	P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells
Paclitaxel	Cytotoxicity	Inhibition of P-glycoprotein (PGP) activity by verapamil or PSC 833 enhances the Cytotoxicity of vincristine@ doxorubicin@ teniposide and taxol [ ADR Type 4 ]	P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells
PSC 833	Cytotoxicity	Inhibition of P-glycoprotein (PGP) activity by verapamil or PSC 833 enhances the Cytotoxicity of vincristine@ doxorubicin@ teniposide and taxol. [ ADR Type 4 ]	P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells
PSC 833	Not Available	[ ADR Type ]
verapamil	Cytotoxicity	Inhibition of P-glycoprotein (PGP) activity by verapamil or PSC 833 enhances the Cytotoxicity of vincristine@ doxorubicin@ teniposide and taxol [ ADR Type 4 ]	P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells

This panel provides information on drug category

Toxicity	Source
Alopecia	Large-scale prediction and testing of drug activity on side-effect targets
Angioedema	Large-scale prediction and testing of drug activity on side-effect targets
Azoospermia	Large-scale prediction and testing of drug activity on side-effect targets
Bone Marrow Failure	Large-scale prediction and testing of drug activity on side-effect targets
Hyperlipidaemia	Large-scale prediction and testing of drug activity on side-effect targets
Mucosal Inflammation	Large-scale prediction and testing of drug activity on side-effect targets
Oligomenorrhoea	Large-scale prediction and testing of drug activity on side-effect targets
Stomatitis	Large-scale prediction and testing of drug activity on side-effect targets

InAADR: Drug-Protein-ADRs database